Tauriga Sciences, Inc. Reports 250%+ Sequential Quarter to Quarter Revenue Growth in its E-Commerce Business Segment
April 08 2020 - 8:52AM
InvestorsHub NewsWire
Tauriga Sciences, Inc. Reports
250%+ Sequential Quarter to Quarter Revenue Growth in its
E-Commerce Business Segment
NEW YORK, NY -- April 8, 2020 -- InvestorsHub NewsWire --
Tauriga Sciences, Inc. (OTCQB: TAUG)
(“Tauriga” or the “Company”), a revenue generating Company that
operates through the development, distribution, and licensing of
proprietary products as well as the evaluation of potential
acquisition opportunities and equity investments, today announced
that its E-Commerce business segment experienced strong revenue
growth, during its most recent completed quarter --
4th Fiscal Quarter 2020 (period: January 1, 2020 –
March 31, 2020). On a sequential Quarter to Quarter basis,
the Company reported revenue growth in excess of 250% with a
corresponding spike in both individual transactions and visitor
traffic on its E-Commerce platform (www.taurigum.com).
In other news, the Company expects to receive its Cannabigerol
(“CBG”) infused Tauri-Gum™ inventory at its E-Commerce fulfillment
center (Upstate New York) – within days. The Company’s CBG
version of Tauri-Gum™ is Peach-Lemon flavor and there have been
substantial expressions of interest (from a broad array of
prospective customers), in this newest product offering.
ABOUT TAURIGA SCIENCES INC.
Tauriga Sciences, Inc. (TAUG)
is a revenue generating, diversified life sciences company, engaged
in several major business activities and initiatives. The
company manufactures and distributes several proprietary retail
products and product lines, mainly focused on the Cannabidiol
(“CBD”) and Cannabigerol (“CBG”) Edibles market segment. The
main product line, branded as Tauri-Gum™, consists of a proprietary
supplement chewing gum that is both Kosher certified and Vegan
formulated (CBD Infused Tauri-Gum™ Flavors: Mint, Blood Orange,
Pomegranate) & (CBG Infused Tauri-Gum™ Flavor:
Peach-Lemon). The Company’s commercialization strategy
consists of a broad array of retail customers, distributors, and a
fast-growing E-Commerce business segment (E-Commerce
website: www.taurigum.com). Please
visit our corporate website, for additional information, as well as
inquiries, at www.tauriga.com.
Complementary to the Company’s retail business, are its two
ongoing biotechnology initiatives. The first one relates to
the development of a Pharmaceutical grade version of Tauri-Gum™,
for nausea regulation (specifically designed to help patients that
are subjected to ongoing chemotherapy treatment). On March
18, 2020, the Company announced that it filed a provisional U.S.
patent application covering its pharmaceutical grade version of
Tauri-Gum™. The Patent, filed with the U.S.P.T.O. is Titled
“MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS
OF TREATMENT”. The second one relates to a collaboration
agreement with Aegea Biotechnologies Inc. for the co-development of
a rapid, multiplexed, Novel Coronavirus (COVID-19) test with
superior sensitivity and selectivity.
The Company is headquartered in New York City and operates a
regional office in Barcelona, Spain. In addition, the Company
operates a full time E-Commerce fulfillment center located in
LaGrangeville, New York.
DISCLAIMER -- Forward-Looking Statements
This press release contains certain “forward-looking statements”
as defined by the Private Securities Litigation Reform Act of 1995
which represent management’s beliefs and assumptions concerning
future events. These forward-looking statements are often indicated
by using words such as “may,” “will,” “expects,” “anticipates,”
believes, “hopes,” “believes,” or plans, and may include statements
regarding corporate objectives as well as the attainment of certain
corporate goals and milestones. Forward-looking statements are
based on present circumstances and on management’s present beliefs
with respect to events that have not occurred, that may not occur,
or that may occur with different consequences or timing than those
now assumed or anticipated. Actual results may differ materially
from those expressed in forward looking statements due to
known and unknown risks and uncertainties, such as are not
guarantees of general economic and business conditions, the ability
to successfully develop and market products, consumer and business
consumption habits, the ability to consummate successful
acquisition and licensing transactions, fluctuations in exchange
rates, and other factors over which Tauriga has little or no
control. Many of these risks and uncertainties are discussed in
greater detail in the “Risk Factors” section of Tauriga’s Form 10-K
and other filings made from time to time with the Securities and
Exchange Commission. Such forward-looking statements are made only
as of the date of this release, and Tauriga assumes no obligation
to update forward-looking statements to reflect subsequent events
or circumstances. You should not place undue reliance on these
forward-looking statements.
Contact:
CONTACT INFORMATION
Tauriga Sciences, Inc.
555 Madison Avenue, 5th Floor
New York, NY 10022
Chief Executive Officer
Mr. Seth M. Shaw
Email: sshaw@tauriga.com
cell # (917) 796 9926
Instagram: @tauri_gum
Twitter: @SethMShaw
Corp. Website: www.tauriga.com
E-Commerce Website: www.taurigum.com
Tauriga Sciences (CE) (USOTC:TAUG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tauriga Sciences (CE) (USOTC:TAUG)
Historical Stock Chart
From Apr 2023 to Apr 2024